Patents Assigned to The United States of America as represented by the Secretary of the Department of Veterans Affairs
  • Publication number: 20190059718
    Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.
    Type: Application
    Filed: March 26, 2018
    Publication date: February 28, 2019
    Applicants: University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affair
    Inventors: Michael D. Abramoff, Meindert Niemeijer, Xiayu Xu, Milan Sonka, Joseph M. Reinhardt
  • Patent number: 10137136
    Abstract: In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 27, 2018
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. Adams, Steven D. Kunkel, Michael Welsh
  • Patent number: 10034936
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 31, 2018
    Assignees: The University of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Publication number: 20180118657
    Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 3, 2018
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. ADAMS, Steven D. KUNKEL, Manish SUNEJA, Michael WELSH
  • Patent number: 9924867
    Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: March 27, 2018
    Assignees: University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Michael D. Abramoff, Melndert Niemeijer, Xiayu Xu, Milan Sonka, Joseph M. Reinhardt
  • Patent number: 9790267
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: October 17, 2017
    Assignees: The Trustees of the University of Pennsylvania, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventor: David Kaplan
  • Patent number: 8870786
    Abstract: Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: October 28, 2014
    Assignees: Oregon Health & Science University, The United States of America as represented by the Secretary of The Department of Veterans Affairs
    Inventors: James A. Henry, Grayson Silaski, David Gray, Edward V. Porsov, Kimberly Owens
  • Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Patent number: 7807458
    Abstract: Described herein are post natal, multilineage inducible cells (MIAMI cells). In some examples, the cells are isolated from non fractionated, adult (males and females 3 to 72 years old) human bone marrow under cell culture conditions, which are believed to resemble an in vivo niche microenvironment in which primitive multipotent cells exist. MIAMI cells have a unique profile of molecular markers, and can be maintained in vitro (for more than 50 population doublings) without detectable changes in their characteristic molecular profile. MIAMI cells can be differentiated into mesodermal, neuroectodermal, and endodermal cell lineages. Methods of isolating, differentiating and using MIAMI cells are also described.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: October 5, 2010
    Assignees: The United States of America as represented by the Secretary of the Department of Veterans Affairs, The University of Miami
    Inventors: Paul C. Schiller, Gianluca D'Ippolito
  • Patent number: 7361493
    Abstract: Embodiments of a method for the production of human urokinase are disclosed. Also disclosed are embodiments of a cell culture well-suited for use with the disclosed method. The method involves culturing urokinase-producing cells, such as immortalized human renal cells, in a cell culture. The cell culture comprises microcarrier structures and a tissue culture medium. The urokinase production is allowed to occur while the cell culture remains relatively static, i.e., the cell culture is not substantially mixed.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: April 22, 2008
    Assignees: The United States of America as represented by the Secretary of the Department of Veterans Affairs, Tulane University
    Inventors: Timothy G. Hammond, Patricia L. Allen
  • Patent number: 7202030
    Abstract: This invention relates to the enzymatic synthesis of oligophenols on solid support by sequential enzymatic addition of reaction solutions containing phenols. The oligomers are then selectively built up on the solid surface. When used in a specific format, the oligomers can be generated in a spatially addressable array, which can then be screened for some type of biological interaction. The synthetic compounds of the present invention are synthesized in a combinatorial manner on solid support using peroxidase or other related enzymatic catalysis, and the products are generated in spatially addressable microarrays. Oligophenols of the present invention have shown significance as potential inhibitors of NADPH oxidase assembly, an enzyme that has been implicated in a wide range of diseases stemming from vascular hyperpermeability.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: April 10, 2007
    Assignees: Rensselaer Polytechnic Institute, The United States of America as represented by the Secretary, Department of Veterans Affairs
    Inventors: Jonathan S. Dordick, Lakshmi Santhanam, Michael G. Hogg, James A. Holland